Log in

NASDAQ:ASRTAssertio Therapeutics Stock Price, Forecast & News

$0.82
0.00 (-0.55 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.81
Now: $0.82
$0.84
50-Day Range
$0.81
MA: $0.89
$1.08
52-Week Range
$0.55
Now: $0.82
$3.55
Volume577,500 shs
Average Volume1.50 million shs
Market Capitalization$66.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASRT
CUSIPN/A
CIKN/A
Phone224-419-7106

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.50 million
Book Value$0.72 per share

Profitability

Net Income$-217,200,000.00

Miscellaneous

EmployeesN/A
Market Cap$66.37 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ASRT News and Ratings via Email

Sign-up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.

Assertio Therapeutics (NASDAQ:ASRT) Frequently Asked Questions

How has Assertio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Assertio Therapeutics' stock was trading at $0.9301 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASRT stock has decreased by 12.3% and is now trading at $0.8155. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Assertio Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assertio Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Assertio Therapeutics.

When is Assertio Therapeutics' next earnings date?

Assertio Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Assertio Therapeutics.

How were Assertio Therapeutics' earnings last quarter?

Assertio Therapeutics, Inc. (NASDAQ:ASRT) announced its earnings results on Monday, May, 11th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.18. The business earned $20.92 million during the quarter, compared to the consensus estimate of $11.30 million. Assertio Therapeutics had a negative return on equity of 110.00% and a negative net margin of 83.99%. View Assertio Therapeutics' earnings history.

What price target have analysts set for ASRT?

1 brokerages have issued twelve-month price targets for Assertio Therapeutics' stock. Their forecasts range from $3.50 to $3.50. On average, they anticipate Assertio Therapeutics' stock price to reach $3.50 in the next year. This suggests a possible upside of 329.2% from the stock's current price. View analysts' price targets for Assertio Therapeutics.

Has Assertio Therapeutics been receiving favorable news coverage?

Media stories about ASRT stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Assertio Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Assertio Therapeutics.

Who are some of Assertio Therapeutics' key competitors?

Who are Assertio Therapeutics' key executives?

Assertio Therapeutics' management team includes the following people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
  • Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)

What is Assertio Therapeutics' stock symbol?

Assertio Therapeutics trades on the NASDAQ under the ticker symbol "ASRT."

How do I buy shares of Assertio Therapeutics?

Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Assertio Therapeutics' stock price today?

One share of ASRT stock can currently be purchased for approximately $0.82.

How big of a company is Assertio Therapeutics?

Assertio Therapeutics has a market capitalization of $66.37 million and generates $229.50 million in revenue each year. The company earns $-217,200,000.00 in net income (profit) each year or ($3.07) on an earnings per share basis.

What is Assertio Therapeutics' official website?

The official website for Assertio Therapeutics is www.assertiotx.com.

How can I contact Assertio Therapeutics?

Assertio Therapeutics' mailing address is 100 South Saunders Road Suite 300, Lake Forest IL, 60045. The company can be reached via phone at 224-419-7106 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.